Malignant gliomas are the most common primary brain tumors. One major problem is that the tumor cells evade the patients’ own immune response. We focus our research upon this. We have developed a glioma cell line with green fluorescent tumor cells that are inoculated into immunocompetent rats, and hereby we follow tumor cell infiltration. Complement activation in malignant gliomas. Our co-operation partner Kurt Osther has seen that human glioma cells express factors suppressing the complement activation. We investigate this in other human cell lines and rat glioma cell lines, and run animal experiments where the complement inactivation is targeted with antibodies. Combated radio-immunotherapy. It is known that low-dose radiotherapy can promote the immune response. We have studied the effect of combined radio-immunotherapy, and seen that this can lead to increased survival, for example when combined with IDO inhibition. IDO is an immune suppressive protein expressed in glioma cells.